Answers are grounded in this paper and cite their sources.
Plain Language SummaryWhat is this summary about?This summary describes the final results from the TALAPRO-2 clinical study. This study tested a combination of two medicines called talazoparib and enzalutamide. These medicines were given together as the first treatment for metastatic castration-resistant prostate cancer (mCRPC) in adult patients. The combination of talazoparib plus enzalutamide was compared with a placebo plus enzalutamide.There were two groups of patients in the TALAPRO-2 study. The first group included patients who may or may not have changes in specific DNA repair genes, called homologous recombination repair (HRR) genes, within their tumors. This group is called the unselected group of patients. The second group included only patients who had changes in specific HRR genes within their tumors. These changes may make cancer cells vulnerable to treatment with talazoparib plus enzalutamide. This summary focuses on the group of patients with changes in specific HRR genes. A separate summary looks at the unselected group.What were the goals of this final analysis?Researchers looked at whether patients receiving talazoparib plus enzalutamide lived longer than patients receiving a placebo plus enzalutamide. The length of time patients live after starting treatment is called overall survival. Researchers were able to look at the final results of the study because the patients had been followed longer. These final results included how long patients lived before their cancer got worse or they died (known as progression-free survival).Researchers also looked at the safety of talazoparib plus enzalutamide, including the number, type, and severity of side effects. Lastly, researchers asked the patients how they felt about their general quality of life.What are the key takeaways?A total of 399 patients with mCRPC and changes in HRR genes within their tumors took part in the study. Patients who took talazoparib plus enzalutamide had a 38% lower chance of dying than those who took a placebo plus enzalutamide. Researchers also looked at a smaller group of patients with changes in certain HRR genes, such as BRCA. Patients with changes in BRCA genes within their tumors who took talazoparib plus enzalutamide had a 50% lower chance of dying than those who took a placebo plus enzalutamide.The most common side effects of talazoparib plus enzalutamide were anemia (low levels of red blood cells), excessive tiredness or exhaustion, low levels of neutrophils (a type of white blood cell), and low levels of platelets (which help to stop bleeding).Clinical trial number: NCT03395197
No takes yet. Share an insight, caveat, or question.
Fizazi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: